| Modified Release Posaconazole in Patients With Cystic Fibrosis (NCT03421366) | Bayside Health | 2018-03-01 |
| A Study of Web and Tablet-based Interactive Audiometry in Adults With CF (NCT04400955) | Royal Brompton & Harefield NHS Foundation Trust | 2018-03-01 |
| Effect of High Frequency Chest Wall Oscillation Vests on Spirometry Measurements (NCT03534986) | International Biophysics Corporation | 2018-02-20 |
| Pharmacokinetics of GLPG3067 in Male Subjects With Cystic Fibrosis. (NCT03589313) | Lakefront Biotherapeutics NV | 2018-02-12 |
| Study of Urinary Predictors of Exacerbations by Biomarkers in Cystic Fibrosis (NCT04297709) | Mologic Ltd | 2018-02-01 |
| Safety, Tolerability, and Pharmacokinetics of PTI-808, PTI-801, and PTI-428 Combination Therapy in Subjects With Cystic Fibrosis (NCT03500263) | Proteostasis Therapeutics, Inc. | 2018-01-30 |
| CHaractErizing CFTR Modulated Changes in Sweat Chloride and Their Association With Clinical Outcomes (NCT03350828) | Nicole Hamblett | 2018-01-15 |
| Effects of Inspiratory Muscle Training on Postural Stability, Balance, Pulmonary Function and Functional Capacity in Children With Cystic Fibrosis (NCT03375684) | Bezmialem Vakif University | 2018-01-02 |
| Effect of Lumacaftor-ivacaftor on Glucose Handling and Tolerance in Cystic Fibrosis Phe508del (NCT02653027) | Massachusetts General Hospital | 2018-01-01 |
| Evaluation of Salt Status in Patients With Cystic Fibrosis (NCT04556162) | University Hospital, Ghent | 2018-01-01 |
| Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis (NCT03451045) | Corbus Pharmaceuticals Inc. | 2017-12-22 |
| An Phase 1 Study to Evaluate the Pharmacokinetic (PK) Profile of FDL169 New Formulations in Healthy Subjects (NCT03424252) | Flatley Discovery Lab LLC | 2017-12-18 |
| Evaluation of Patient Access to People With Cystic Fibrosis (CF) and Healthcare Professionals (NCT06122025) | The Leeds Teaching Hospitals NHS Trust | 2017-12-11 |
| Impact of the Introduction of ORKAMBI on Anxiety, Depression, Quality of Life and Adherence of Adolescents and Young Adults (NCT03659214) | Assistance Publique - Hôpitaux de Paris | 2017-12-01 |
| GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis (NCT03474042) | Lakefront Biotherapeutics NV | 2017-11-29 |
| Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria (NCT03219164) | Gilead Sciences | 2017-11-28 |
| Prevalence and Impact of Depression and Anxiety in Cystic Fibrosis (NCT03424486) | Assistance Publique - Hôpitaux de Paris | 2017-11-23 |
| Simplification of CF-related Diabetes Screening at Home (NCT03227094) | Institut de Recherches Cliniques de Montreal | 2017-11-13 |
| Losartan and Inflammation in Cystic Fibrosis (NCT03206788) | University of Miami | 2017-11-11 |
| The Effects of Discontinuation of Vitamin K Antagonists on the Rate of Elastin Degradation (NCT03285100) | Canisius-Wilhelmina Hospital | 2017-10-31 |
| MUCOviscidose EXacerbation Outils Connectés Education Thérapeutique (NCT03304028) | Institut National de la Santé Et de la Recherche Médicale, France | 2017-10-20 |
| Fidgety Movements in Cystic Fibrosis (NCT03381157) | Hacettepe University | 2017-10-02 |
| Utility of Point Shear-wave Elastography to Assess for Hepatic & Pancreatic Fibrosis in Pediatric CF Patients (NCT03264950) | University of Manitoba | 2017-10-01 |
| 1STST and Muscle Weakness in CF Patients (NCT03117764) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2017-10-01 |
| A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis (NCT03309358) | Synspira, Inc. | 2017-09-28 |
| Longitudinal Analysis of Respiratory and Intestinal Microbiome in Cystic Fibrosis (NCT03335202) | University of Kiel | 2017-09-28 |
| AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis (NCT03181932) | Savara Inc. | 2017-09-20 |
| Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF) (NCT02769637) | University of Colorado, Denver | 2017-09-07 |
| Relationship of Skeletal Muscle Thickness, Strength, and Diaphragm Function in Adults With CF (NCT04892485) | Marmara University | 2017-09-01 |
| Pharmacokinetic and Pharmacodynamic Analysis of Ceftaroline in Children and Adolescents With Cystic Fibrosis (NCT03771313) | Children's Hospital Medical Center, Cincinnati | 2017-09-01 |
| Sit-to-stand Test in Cystic Fibrosis Children and Adolescents (NCT03069625) | Groupe Hospitalier du Havre | 2017-08-31 |
| Efficacy and Safety of Tigerase® vs. Pulmozyme® in Patients With Cystic Fibrosis (NCT04468100) | AO GENERIUM | 2017-08-30 |
| Interactive Video Game Responses in Cystic Fibrosis (NCT03229213) | Pontificia Universidade Católica do Rio Grande do Sul | 2017-08-30 |
| Program Of Exercises During The Hospitalization Of Children And Adolescents With Cystic Fibrosis (NCT03273959) | Hospital de Clinicas de Porto Alegre | 2017-08-28 |
| A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects (NCT03093714) | Flatley Discovery Lab LLC | 2017-08-23 |
| A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis (NCT03224351) | Vertex Pharmaceuticals Incorporated | 2017-08-08 |
| An Efficacy and Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis (NCT03229252) | Spyryx Biosciences, Inc. | 2017-08-01 |
| Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis on KALYDECO® as Background Therapy (NCT03258424) | Proteostasis Therapeutics, Inc. | 2017-07-28 |
| A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation (NCT03068312) | Vertex Pharmaceuticals Incorporated | 2017-07-18 |
| Perceived Impact of Art Therapy in Patients With Cystic Fibrosis and in Professional Interdisciplinary Teams Taking Care of Them. (NCT02932657) | Nantes University Hospital | 2017-06-29 |
| Pharmacokinetics of GLPG2737 in Male Subjects With Cystic Fibrosis (NCT03450720) | Lakefront Biotherapeutics NV | 2017-06-28 |
| A Study to Assess the Safety, Tolerability and PK Profile of FDL176 in Healthy and CF Participants (NCT03173573) | Flatley Discovery Lab LLC | 2017-06-27 |
| Airway Alkalinization and Nasal Colonization (NCT03078088) | Lakshmi Durairaj | 2017-06-15 |
| Evaluation of Short Antibiotic Combination Courses Followed by Aerosols in Cystic Fibrosis (NCT03066453) | University Hospital, Lille | 2017-06-13 |
| Non-respiratory Comorbidities Observed in Pulmonary French Transplant Patients With Cystic Fibrosis (NCT03357913) | Hospices Civils de Lyon | 2017-06-01 |
| Bacteriological Link Between Upper and Lower Airways in Cystic Fibrosis and Primary Ciliary Dyskinesia (NCT03494894) | Centre Hospitalier Intercommunal Creteil | 2017-06-01 |
| The Sinonasal Cavity as a Reservoir for Upper Airway Bacterial Development (NCT03016689) | University of Minnesota | 2017-05-31 |
| A Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis (NCT03056989) | Spyryx Biosciences, Inc. | 2017-05-31 |
| A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF) (NCT03150719) | Vertex Pharmaceuticals Incorporated | 2017-05-24 |
| A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (NCT03125395) | Vertex Pharmaceuticals Incorporated | 2017-05-12 |
| Multiple Breath Washout, a Clinimetric Dataset (NCT03320382) | Imperial College London | 2017-05-05 |
| MRI in Cystic Fibrosis and Primary Ciliary Dyskinesia (NCT03279965) | Royal Brompton & Harefield NHS Foundation Trust | 2017-05-05 |
| Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis (NCT03140527) | Proteostasis Therapeutics, Inc. | 2017-04-10 |
| Clearance of 25-hydroxyvitamin D in Cystic Fibrosis (NCT03104855) | University of Washington | 2017-04-03 |
| A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis (NCT03119649) | Lakefront Biotherapeutics NV | 2017-03-18 |
| MN4000 for Treatment of CF and MND Patients in the Home Setting (NCT03797677) | Hill-Rom | 2017-03-09 |
| Lung Clearance Index (LCI) in Pediatric Patients With Obstructive Lung Disease (NCT02950116) | Universitair Ziekenhuis Brussel | 2017-03-09 |
| Clinical Effects of Exercise Program Added to Pulmonary Rehabilitation in Patients With Cystic Fibrosis (NCT03295201) | Marmara University | 2017-03-05 |
| Impact of Early Implementation of Narrative Medicine Techniques on Patient Centered Attitudes of Medical Students (NCT03041571) | University of Florida | 2017-03-01 |
| Tobramycin Delivered by Nebulized Sonic Aerosol for Chronic Rhinosinusitis Treatment of Cystic Fibrosis Patients (NCT02888730) | Virginie ESCABASSE | 2017-02-16 |
| Air Pollution and Children With Cystic Fibrosis (NCT03853629) | Queen Mary University of London | 2017-02-15 |
| BI 443651 Multiple Rising Dose in Healthy Volunteers Followed by a Cross-over in CF Subjects (NCT02976519) | Boehringer Ingelheim | 2017-02-15 |
| A Multi-Center Study of the CF Quantum® Sweat Test System (NCT02404714) | Polychrome Medical, Inc. | 2017-02-08 |
| A Study of RPL554 in Patients With Cystic Fibrosis (NCT02919995) | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 2017-02-08 |
| Researching the Effects of Airway Clearance Therapies in Cystic Fibrosis (NCT03078127) | University of North Carolina, Chapel Hill | 2017-02-01 |
| Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation (NCT03061331) | Vertex Pharmaceuticals Incorporated | 2017-01-31 |
| PTC Study to Evaluate Ataluren in Combination With Ivacaftor (NCT03256968) | University of Alabama at Birmingham | 2017-01-27 |
| Development and Validation of a Disease Specific PROM to Assess Abdominal Involvement in Patients With CF (CFAbd-Score) (NCT03052283) | Medizinische Hochschule Brandenburg Theodor Fontane | 2017-01-26 |
| A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis (NCT03227471) | Vertex Pharmaceuticals Incorporated | 2017-01-23 |
| Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance (NCT02955888) | Liminal BioSciences Ltd. | 2017-01-03 |
| Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis (NCT02894684) | Liverpool Heart and Chest Hospital NHS Foundation Trust | 2017-01-01 |
| Gynecological Health Improvement of Adult Women With Cystic Fibrosis (NCT03892304) | Hospices Civils de Lyon | 2017-01-01 |
| Multilevel Models of Therapeutic Response in the Lungs (NCT02947126) | Tim Corcoran | 2017-01-01 |
| A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis (NCT03045523) | Lakefront Biotherapeutics NV | 2017-01-01 |
| Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease (NCT02730793) | Virginia Commonwealth University | 2017-01-01 |
| Real Life Evaluation of the Multi-organ Effects of Lumacaftor/Ivacaftor on F508del Homozygous Cystic Fibrosis Patients. (NCT04623879) | Carmel Medical Center | 2016-12-29 |
| Effect of a Family Empowerment Program on Coping, Problem Solving in Parents, and Quality of Life in Children With Cystic Fibrosis (NCT03800459) | Selcuk University | 2016-12-14 |
| Identification of Predictive Epigenetic Biomarkers of Lung Disease Severity in Cystic Fibrosis (NCT02976714) | University Hospital, Montpellier | 2016-12-12 |
| Nutritional Intervention and Glycemic Improvement in Patients With Pre-diabetic Cystic Fibrosis. (NCT03205904) | Hospital de Clinicas de Porto Alegre | 2016-12-12 |
| Parameters to Assess Response to Intra-Venous Antibiotic Treatment for Pulmonary Exacerbations in Cystic Fibrosis (NCT04016571) | Belfast Health and Social Care Trust | 2016-12-01 |
| The Effect of Proprioceptive Neuromuscular Facilitation (PNF) Technique for Children With Chronic Pulmonary Diseases. (NCT03420209) | Istanbul University | 2016-12-01 |
| Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations (NCT02971839) | Vertex Pharmaceuticals Incorporated | 2016-12-01 |
| Short-term Effects of Physiotherapy on LCI (NCT03760120) | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 2016-11-21 |
| Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis (NCT02759562) | Gilead Sciences | 2016-11-04 |
| A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF) (NCT02953314) | Vertex Pharmaceuticals Incorporated | 2016-11-01 |
| A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis (NCT03029455) | Vertex Pharmaceuticals Incorporated | 2016-11-01 |
| A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects (NCT03056326) | Chiesi Farmaceutici S.p.A. | 2016-11-01 |
| A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis (NCT02951195) | Vertex Pharmaceuticals Incorporated | 2016-11-01 |
| An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations (NCT02934698) | Medical University of South Carolina | 2016-11-01 |
| A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis (NCT02951182) | Vertex Pharmaceuticals Incorporated | 2016-10-01 |
| MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9) (NCT02934139) | Nivalis Therapeutics, Inc. | 2016-10-01 |
| Hyperpolarized Xenon Imaging in Patients With Cystic Fibrosis (NCT02912637) | Papworth Hospital NHS Foundation Trust | 2016-10-01 |
| A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation (NCT02875366) | Vertex Pharmaceuticals Incorporated | 2016-09-01 |
| Improving Outcome Measures For Adult CF ACT Trials (NCT02721498) | Royal Brompton & Harefield NHS Foundation Trust | 2016-09-01 |
| EASY: Extended Access to Sollpura Over Years (NCT02823964) | Anthera Pharmaceuticals | 2016-09-01 |
| IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy (NCT02918409) | National Jewish Health | 2016-08-26 |
| The Alfred Step Test Exercise Protocol (A-STEP), for Adults With Cystic Fibrosis. (NCT02717650) | The Alfred | 2016-08-25 |
| Safety and Tolerability Study of Allogeneic Mesenchymal Stem Cell Infusion in Adults With Cystic Fibrosis (NCT02866721) | University Hospitals Cleveland Medical Center | 2016-08-01 |
| The Effect of Combination Lumacaftor and Ivacaftor on Markers of Hyperglycemia (NCT02858843) | Massachusetts General Hospital | 2016-08-01 |
| Adherence to Airway Clearance. Novel Approaches to Improving Adherence (NCT02906826) | University of British Columbia | 2016-08-01 |